Medipharm Labs (TSX: LABS) has closed the bought deal financing that it announced and then later upsized earlier this week. The company managed to raise total gross proceeds of $33.4 million under the financing.
The financing saw units of the company sold at a price of $0.58, with each unit containing one common share and one common share purchase warrant. Each warrant is valid for a period of 2 years from the date of issuance at a price of $0.70 per common share.
The financing saw a total of 57.5 million units sold, while the over-allotment option was exercised in full.
Proceeds from the financing are to be used to expand the firms product portfolio, pharmaceutical registrations, R&D for clinical trials, sales and marketing, as well as working capital and general corporate purposes.
Medipharm Labs last traded at $0.49 on the TSX.
.Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.